AJOVista LLC Makes New Investment in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

AJOVista LLC acquired a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 5,233 shares of the company’s stock, valued at approximately $57,000.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Deerfield Management Company L.P. Series C purchased a new position in iTeos Therapeutics during the third quarter valued at approximately $7,917,000. 683 Capital Management LLC increased its holdings in shares of iTeos Therapeutics by 38.5% during the 3rd quarter. 683 Capital Management LLC now owns 810,000 shares of the company’s stock valued at $8,870,000 after purchasing an additional 225,000 shares in the last quarter. Vontobel Holding Ltd. lifted its stake in shares of iTeos Therapeutics by 41.9% in the 4th quarter. Vontobel Holding Ltd. now owns 220,056 shares of the company’s stock valued at $2,410,000 after purchasing an additional 64,981 shares during the period. Algert Global LLC boosted its holdings in iTeos Therapeutics by 131.3% during the third quarter. Algert Global LLC now owns 96,180 shares of the company’s stock worth $1,053,000 after buying an additional 54,590 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in iTeos Therapeutics by 2.3% during the third quarter. Vanguard Group Inc. now owns 1,813,759 shares of the company’s stock valued at $19,861,000 after buying an additional 40,407 shares during the period. Institutional investors and hedge funds own 97.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ITOS. HC Wainwright reiterated a “buy” rating and issued a $44.00 price objective on shares of iTeos Therapeutics in a research report on Thursday, March 7th. Wedbush reaffirmed an “outperform” rating and issued a $18.00 price target (down previously from $25.00) on shares of iTeos Therapeutics in a report on Wednesday, March 6th.

iTeos Therapeutics Price Performance

Shares of NASDAQ ITOS opened at $11.66 on Monday. The firm has a fifty day moving average of $11.55 and a 200 day moving average of $10.70. iTeos Therapeutics, Inc. has a one year low of $8.20 and a one year high of $18.24.

iTeos Therapeutics (NASDAQ:ITOS) last released its earnings results on Wednesday, March 6th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.18. As a group, equities research analysts forecast that iTeos Therapeutics, Inc. will post -4.76 earnings per share for the current fiscal year.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.